Association of Adjuvant Tamoxifen and Aromatase Inhibitor Therapy With Contralateral Breast Cancer Risk Among US Women With Breast Cancer in a General Community Setting.

ABSTRACT:

Importance

Within 10 years after breast cancer diagnosis, roughly 5% of patients develop contralateral breast cancer (CBC). Randomized trials have found that therapy including tamoxifen citrate and aromatase inhibitors (AIs) reduces CBC risk. But little is known about the magnitude and duration of protective associations within the context of real-world clinical management settings, where varying durations of and gaps in treatment are common.

Objective

To determine the association between adjuvant tamoxifen and AI therapy and CBC risk within a general community setting.

Design, setting, and participants

A retrospective cohort study of CBC risk among 7541 patients diagnosed with a first primary unilateral invasive breast cancer at Kaiser Permanente Institute for Health

SUBMITTER: Gierach GL 

PROVIDER: S-EPMC5757540 | biostudies-literature | 2017 Feb

REPOSITORIES: biostudies-literature